
|Videos|July 4, 2021
Dr. Ramasamy discusses investigational oral testosterone treatment
Author(s)Urology Times staff
Ranjith Ramasamy, MD, comments on SOV2012-F1 (Kyzatrex), an oral testosterone undecanoate soft gelatin capsule.
Advertisement
In this video, Ranjith Ramasamy, MD, discusses SOV2012-F1 (Kyzatrex), an oral testosterone undecanoate soft gelatin capsule for which the FDA recently accepted a new drug application. Ramasamy is an associate professor of urology and director of male reproductive medicine and surgery at the University of Miami Miller School of Medicine.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care
4
The Expert APProach: Advancing APP Leadership and Expertise in Urology, With Susanne Quallich, PhD, ANP-BC, NP-C
5










